Tiziana Life Sciences

TLSA

Market cap $201M

Overview Fund Activity

1.72 USD

+0.06

3.61%

At close Updated Sep 18, 10:35 AM EDT

1 day

3.61%

5 days

-7.53%

1 month

-8.99%

3 months

7.5%

6 months

13.16%

Year to date

152.64%

1 year

60.75%

5 years

-56.23%

10 years

2.99%

About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Employees: 9

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

24% more capital invested

Capital invested by funds: $3.25M [Q1] → $4.03M (+$781K) [Q2]

1.19% more ownership

Funds ownership: 2.71% [Q1] → 3.9% (+1.19%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

9% less funds holding

Funds holding: 32 [Q1] → 29 (-3) [Q2]

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

See Fund Rankings

Financial journalist opinion

Based on 5 articles about TLSA published over the past 30 days

Proactive Investors

Tiziana Life Sciences awarded DoD grant to advance intranasal therapy for spinal cord injury

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been awarded a US Department of Defense (DoD) research grant to advance its intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). The grant will support a three-year study examining the therapy in the acute phase of SCI, focusing on patients who present immediately following injury.

Tiziana Life Sciences awarded DoD grant to advance intranasal therapy for spinal cord injury

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 14,848 shares of Tiziana common stock at a price of $1.65 per share in the open market, correcting todays earlier press release. This brings his current purchased shares total to 193,848.

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 193,848 shares of Tiziana common stock at a price of $1.65 per share in the open market.

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life Sciences Announces Purchase of Shares by Chairman

BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 25,000 common shares at $1.60 per share, bringing his total holding to 43,277,143 common shares, which is 36.28% of issued share capital.

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Proactive Investors

Tiziana Life Sciences doses first MSA patient in new trial – ICYMI

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about the company's latest milestone: dosing the first patient in its Phase 2a clinical trial targeting multiple system atrophy (MSA), a rare and fatal neurodegenerative condition with no approved treatment. Elrifi explained the trial involves the company's investigational monoclonal antibody, Foralumab, which is administered intranasally and aims to reduce neuroinflammation.

Tiziana Life Sciences doses first MSA patient in new trial – ICYMI

Proactive Investors

Tiziana Life Sciences doses first patient in Phase 2a MSA trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System Atrophy (MSA). The trial is being conducted at Brigham and Women's Hospital in Boston, Massachusetts.

Tiziana Life Sciences doses first patient in Phase 2a MSA trial

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients living with Multiple System Atrophy (MSA) at Brigham and Women's Hospital in Boston, Massachusetts.

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Proactive Investors

Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the US Food & Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). The Phase 2a study is a six-month, open-label clinical trial designed to evaluate the effects of intranasal foralumab on microglial activation, clinical outcomes, and safety in MSA patients.

Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is pleased to announce that the U.S. Food & Drug Administration (FDA) have approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Multiple System Atrophy is an unmet medical need as there are currently no FDA approved therapies to treat this life limiting, orphan designated disease.

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

See News Rankings

Charts implemented using Lightweight Charts™